The Seebri, Onbrize and Ultibro products are indicated for COPD symptoms and will be manufactured by Novartis for Glenmark's Brazilian subsidiary
Mumbai-based Glenmark Pharmaceuticals has announced that its Brazilian subsidiary entered into an exclusive partnership agreement with Novartis Biosciences. The deal will see Novartis manufacture three of Glenmark's respiratory products indicated for the treatment of the chronic obstructive pulmonary disease (COPD) symptoms.
Glenn Saldanha, Chairman and Managing Director of Glenmark Pharmaceuticals, said: “This arrangement with a leading global pharmaceutical company will strengthen our respiratory franchise in Brazil.”
The products involved in the agreement are Seebri (Glycopyrronium bromide), Onbrize (Indacaterol) and Ultibro (a combination of Indacaterol and Glycopyrronium), which are indicated for relief of symptoms in adults with COPD.
Under the terms of the agreement, Novartis remains the holder of the registration of these medicines and will be responsible to manufacture them with all technical excellence in line with its global commitment to quality, effectiveness and safety.
Glenmark will be responsible for promoting, commercialising and distributing of these products in Brazil when the agreement comes into effect on 1 July 2019 onwards.